Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H27NO5.ClH |
Molecular Weight | 397.893 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2
InChI
InChIKey=KSQIAZKOUOEHSA-UHFFFAOYSA-N
InChI=1S/C20H27NO5.ClH/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3;/h8-9,12H,5-7,10-11,13H2,1-4H3;1H
DescriptionSources: http://lekarstwo.ru/en/preparati/carbocromenum.htmlCurator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219
Sources: http://lekarstwo.ru/en/preparati/carbocromenum.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219
Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: WP1884 Sources: http://www.ncbi.nlm.nih.gov/pubmed/947200 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Intensain Approved UseIndications for use: Angina without expressed stenotic process protracted and prolonged attacks, postinfarction period. |
PubMed
Title | Date | PubMed |
---|---|---|
Cardioprotective effects of carbocromen in awake and anesthetized dogs with amitriptyline poisoning. | 1985 Jul-Aug |
|
Protective actions of carbocromene against amitriptyline-induced cardiotoxicity in anesthetized rats. | 1986 Jan |
|
Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level. | 2001 Apr 27 |
|
Intradermal injection vs. oral treatment of tinnitus. | 2001 Jul-Aug |
|
Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits. | 2001 Sep |
|
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography. | 2002 Feb 5 |
|
Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats. | 2003 Mar |
|
Preparation and characterization of solid lipid nanoparticles containing cloricromene. | 2003 Oct-Dec |
|
A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat. | 2004 Apr 16 |
|
Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. | 2004 Jul |
|
In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. | 2004 Jun 18 |
|
Protective effects of a coumarin derivative in diabetic rats. | 2009 Aug |
|
Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins. | 2010 Jan 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://lekarstwo.ru/en/preparati/carbocromenum.html
Inside after food: 0,075 - 0,15 g (1 - 2 tablets) 3 times a day.
In more severe cases, to begin receiving 0.15 g 4 times a day, and after improving the dose is reduced to 0.075 g of 3 - 4 times daily. It is noted that the effect of the drug increases (to 10 - 30th day) and lasts a long time.
Take in a few weeks or months (up to 6 months).
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6279121
In bovine heart mitochondria ho/h-1 ratios in repeated scans increased in presence of carbocromen (20--40 umol/l)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C166807
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
81980
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
12603
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
52C937V399
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
100000084871
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
DTXSID2048749
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL163672
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
211-511-5
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
SUB01048MIG
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
m3513
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
655-35-6
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY | |||
|
110430
Created by
admin on Fri Dec 15 15:13:46 GMT 2023 , Edited by admin on Fri Dec 15 15:13:46 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD